Latest Posts
About This Stock
More About This Stock
Read
Read
Read
MicroMarvel: MacroGenics Confuses Wall Street
Article By:
Jim Van Meerten
Monday, February 5, 2024 11:29 AM EDT
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
In this article: MGNX
Week In Review: BeiGene Forges $1.3 Billion Bi-Specific Antibody Deal With Zymeworks
Article By:
ChinaBio® Today
Saturday, December 1, 2018 4:44 PM EDT
BeiGene of Beijing announced cancer drug deals worth up to $1.3 billion with Vancouver's Zymeworks. BeiGene will acquire Asian rights to two bispecific antibodies from Zymeworks and will have rights to three to-be-discovered bispecific candidates.
Morning Call For Tuesday, Dec. 27
Article By:
Jim Van Meerten
Tuesday, December 27, 2016 9:46 AM EDT
Mar E-mini S&Ps (ESH17 +0.06%) are up +0.06% and European stocks are up +0.10% in thin holiday trade. Markets in the UK, Australia and Hong Kong are closed today for holiday.